Comparative Pharmacology
Head-to-head clinical analysis: EMPAVELI versus FABHALTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAVELI versus FABHALTA.
EMPAVELI vs FABHALTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegcetacoplan is a complement C3 inhibitor that binds to complement component C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
Fabhalta (iptacopan) is a complement factor B inhibitor that binds to factor B and prevents the formation of the alternative pathway C3 convertase, thereby inhibiting complement alternative pathway activation.
1080 mg subcutaneously once weekly for 2 weeks, then 1080 mg subcutaneously every 2 weeks thereafter.
200 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 days. This supports once-weekly subcutaneous dosing, achieving steady-state concentrations after 3-4 weeks of weekly administration.
Terminal elimination half-life is approximately 8 hours (range 6-10 hours), supporting twice-daily dosing for sustained complement inhibition.
Primarily excreted unchanged in urine (approximately 60-70% of administered dose) and feces (approximately 20-30% as parent drug and metabolites). Less than 1% is recovered as metabolites.
Primarily renal (approximately 70% as unchanged drug) and biliary/fecal (approximately 30% as metabolites).
Category C
Category C
Complement Inhibitor
Complement Inhibitor